JP2022514499A5 - - Google Patents

Info

Publication number
JP2022514499A5
JP2022514499A5 JP2021533517A JP2021533517A JP2022514499A5 JP 2022514499 A5 JP2022514499 A5 JP 2022514499A5 JP 2021533517 A JP2021533517 A JP 2021533517A JP 2021533517 A JP2021533517 A JP 2021533517A JP 2022514499 A5 JP2022514499 A5 JP 2022514499A5
Authority
JP
Japan
Prior art keywords
cdr2
seq
nos
cdr3 sequences
sequences described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533517A
Other languages
English (en)
Japanese (ja)
Other versions
JP7535045B2 (ja
JP2022514499A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053036 external-priority patent/WO2020123011A1/en
Publication of JP2022514499A publication Critical patent/JP2022514499A/ja
Publication of JP2022514499A5 publication Critical patent/JP2022514499A5/ja
Priority to JP2024077880A priority Critical patent/JP7805395B2/ja
Application granted granted Critical
Publication of JP7535045B2 publication Critical patent/JP7535045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533517A 2018-12-13 2019-09-25 抗il-27抗体及びその使用 Active JP7535045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077880A JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779341P 2018-12-13 2018-12-13
US62/779,341 2018-12-13
PCT/US2019/053036 WO2020123011A1 (en) 2018-12-13 2019-09-25 Anti-il-27 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077880A Division JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2022514499A JP2022514499A (ja) 2022-02-14
JP2022514499A5 true JP2022514499A5 (https=) 2022-10-20
JP7535045B2 JP7535045B2 (ja) 2024-08-15

Family

ID=71075792

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533517A Active JP7535045B2 (ja) 2018-12-13 2019-09-25 抗il-27抗体及びその使用
JP2024077880A Active JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077880A Active JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Country Status (14)

Country Link
US (2) US12358978B2 (https=)
EP (1) EP3894440A4 (https=)
JP (2) JP7535045B2 (https=)
KR (1) KR102933484B1 (https=)
CN (1) CN113544151B (https=)
AU (1) AU2019399474A1 (https=)
BR (1) BR112021011393A2 (https=)
CA (1) CA3121420A1 (https=)
EA (1) EA202191666A1 (https=)
IL (1) IL283875A (https=)
MA (1) MA54469A (https=)
MX (1) MX2021006980A (https=)
SG (1) SG11202105161YA (https=)
WO (1) WO2020123011A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022003719A (es) * 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
US12240897B2 (en) * 2020-09-22 2025-03-04 Institute For Cancer Research Treatment of non-alcoholic steatohepatitis (NASH) with IL-27 antibody
US20240025987A1 (en) * 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) * 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
KR20250034106A (ko) * 2022-08-03 2025-03-10 화이자 인코포레이티드 항-il27r 항체 및 그의 사용 방법
CN120500625A (zh) * 2022-11-01 2025-08-15 表层肿瘤学有限责任公司 治疗肿瘤的方法
WO2026055167A1 (en) * 2024-09-05 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055168A1 (en) * 2024-09-06 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and uses and doses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20050214296A1 (en) 2004-02-17 2005-09-29 Schering Corporation Methods of modulating cytokine activity; related reagents
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011133931A1 (en) * 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
AU2012205384B2 (en) * 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
US20190270802A1 (en) * 2016-10-21 2019-09-05 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist
TN2019000164A1 (en) * 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
CN112512571B (zh) * 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途

Similar Documents

Publication Publication Date Title
JP2022514499A5 (https=)
JP2022050618A5 (https=)
JP6345787B2 (ja) 抗ang2抗体とcd40アゴニストとの併用療法
HRP20220014T1 (hr) Postupci liječenja raka kože davanjem inhibitora pd-1
JP2020516240A5 (https=)
JP2019515008A5 (https=)
FI3618863T3 (fi) Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
JP2023543152A5 (https=)
DK2608808T3 (en) TREATMENT OF NEOPLASTIC DISEASES
RU2019104980A (ru) Анти-icos антитела
JP7138094B2 (ja) マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
US20220396623A1 (en) Uses of anti-icos antibodies
CN110981958A (zh) 一种pd-l1抗体
WO2015119841A1 (en) Role of il-23 and pd-1 in autoreactive immune response
JP2022523804A (ja) がんの処置における増強された有効性のためのil-4/il-13経路阻害剤
KR20240038991A (ko) 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합
JP2022512384A5 (https=)
JP7801225B2 (ja) 抗tnfr2抗体及びその使用
CN119997974A (zh) 一种异源二聚体融合蛋白及其应用
CN117980336A (zh) 抗tnfr2抗体及其用途
US20250340641A1 (en) Uses of anti-icos antibodies
JP2023538105A (ja) Cd40アゴニスト抗体及び使用方法
JP2023512151A5 (https=)
CN114616245A (zh) 一种抗cd38的抗体及其用途
CN118542937A (zh) 抗αvβ3抗体和抗PD-1抗体的联合药物